Phase 2 RCT | Efficacy and safety of low-dose Interleukin 2 for primary Sjögren syndrome.
17 Nov, 2022 | 12:20h | UTCCommentary: Sjogren’s Responds to Cytokine Treatment, Early Data Show — Phase II trial signals possible breakthrough for hard-to-treat illness – MedPage Today (free registration required)